A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
In this study, the investigators want to determine if N-acetylcysteine(NAC), given
intravenously, will decrease complications in patients with Thrombotic Thrombocytopenia
Purpura (TTP) who are receiving treatment with therapeutic plasma exchange (TPE). The
investigators want to determine, through anti-oxidant activity, if NAC will have additional
efficacy in TTP by improving cleavage of the patients' VWF by ADAMTS13, and preventing
propagation of platelet/VWF strings. This will be manifest by a more rapid improvement in the
patient's platelet count, decrease in number of days requiring TPE, and decrease in
microvascular thrombotic complications. The investigators will additionally: 1) Assess safety
of NAC by evaluating subjects for adverse events and significant adverse events 2) Determine
effects on TTP by measuring clinical and research laboratory values 3) Determine drug effects
by measuring clinical and research laboratory values.